CLINICAL_TRIALS
ClinicalTrials.gov record update
A PHASE II STUDY OF G3139 (GENASENSE™, NSC # 683428 IND # 58842) + IMATINIB MESYLATE (GLEEVEC®, STI571) IN PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT00049192
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:35:30.073381+00:00
- Published At
- 2013-06-04T00:00:00+00:00
- Record Updated At
- 2013-06-04
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Chronic Phase Chronic Myelogenous Leukemia", "Relapsing Chronic Myelogenous Leukemia"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2013-06-04"- protocolSection.identificationModule.nctId
"NCT00049192"- protocolSection.identificationModule.officialTitle
"A PHASE II STUDY OF G3139 (GENASENSE\u2122, NSC # 683428 IND # 58842) + IMATINIB MESYLATE (GLEEVEC\u00ae, STI571) IN PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA"- protocolSection.statusModule.overallStatus
"COMPLETED"- protocolSection.designModule.phases
["PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.